10-Q: Clene Inc. Reports Q1 2025 Financial Results and Provides Clinical Program Updates

Clene Inc. reports a net loss of $751,000 for Q1 2025, provides updates on its clinical programs, and acknowledges substantial doubt about its ability to continue as a going concern.

Summary

• Clene Inc. reported a net loss of $751,000 for the quarter ended March 31, 2025, compared to a net loss of $11.08 million for the same period in 2024.
• The company's cash and cash equivalents totaled $9.8 million as of March 31, 2025, down from $12.2 million at the end of 2024.
• Revenue increased to $81,000 from $73,000 in the prior year.
• Research and development expenses decreased significantly to $1.48 million from $5.87 million in 2024.
• The company acknowledges substantial doubt about its ability to continue as a going concern within the next twelve months without additional financing.
• Clene is exploring various financing options, including equity and debt financing, licensing agreements, and utilizing existing at-the-market facilities.
• The company is preparing for a potential NDA submission for CNM-Au8 in ALS in Q4 2025 and plans to commence a confirmatory Phase 3 trial in the second half of 2025.
• Enrollment concluded in January 2025 for the second dosing cohort of REPAIR-MS, with topline results expected in mid-2025.
• Subsequent to March 31, 2025, Clene sold 287,927 shares of Common Stock, generating gross proceeds of $0.9 million, and paid commissions of $13,000 under its ATM Agreements.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has reduced its net loss and R&D expenses, the acknowledgement of substantial doubt about its ability to continue as a going concern and the Nasdaq listing deficiency are significant concerns. The positive clinical data updates are encouraging but do not outweigh the financial risks.

Positives

• Net loss significantly decreased from $11.08 million in Q1 2024 to $751,000 in Q1 2025.
• Research and development expenses decreased by 75%, indicating potential cost management.
• The company is actively pursuing a potential accelerated approval pathway for CNM-Au8 in ALS.
• New data from the VISIONARY-MS trial shows evidence of remyelination and neuronal repair in MS patients treated with CNM-Au8.
• Revenue increased to $81,000 from $73,000 in the prior year.

Negatives

• The company acknowledges substantial doubt about its ability to continue as a going concern without additional financing.
• Cash and cash equivalents decreased to $9.8 million as of March 31, 2025.
• The company does not satisfy all continued listing requirements of Nasdaq.
• The company has material weaknesses in internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• Failure to regain compliance with Nasdaq listing requirements could result in delisting.
• Material weaknesses in internal control over financial reporting could lead to financial misstatements.
• Clinical trial results may not be favorable, and regulatory approvals may not be obtained.
• The company faces significant competition in the pharmaceutical industry.

Future Outlook

Clene is preparing for a potential NDA submission for CNM-Au8 in ALS in Q4 2025 and plans to commence a confirmatory Phase 3 trial in the second half of 2025. The company expects to meet with the FDA in an end of Phase 2 meeting in the third quarter of 2025 regarding REPAIR-MS.

Management Comments

• Management believes the condensed consolidated financial statements fairly represent, in all material respects, the company's financial condition, results of operations, and cash flows.
• Management continues to be actively engaged and committed to taking the steps necessary to remediate the control deficiencies that constituted the above material weaknesses.

Industry Context

The report notes the limited clinical successes and lack of curative therapies for ALS, highlighting the unmet need in this area. The failure of two treatments in the HEALEY ALS Platform Trial underscores the challenges in developing effective ALS therapies.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards.
• The document does not provide specific comparisons to comparable companies.
• The document does not provide specific comparisons to global benchmarks.

Related Party Transactions

• Total revenue under the Supply and License Agreements during the three months ended March 31, 2025 and 2024 was as follows: Three Months Ended March 31, (in thousands) 2025 2024 Product revenue from related parties $ 63 $ 43 Royalty revenue from related parties 17 29 Total revenue from related parties $ 80 $ 72

Stakeholder Impact

• Shareholders face the risk of delisting from Nasdaq and potential dilution from future equity offerings.
• Employees may be affected by cost-saving initiatives, including potential staff reductions.
• Customers of Clene's dietary supplements may see changes in product availability or pricing.
• Suppliers and creditors face increased risk due to the company's going concern uncertainty.

Next Steps

• Provide data from the ongoing EAPs and believe we can address the FDAs requests.
• Meet with the FDA in the second quarter of 2025 to review and finalize our statistical analysis plan for the EAP NfL biomarker analyses.
• Commence a confirmatory Phase 3 trial, RESTORE-ALS, in the second half of 2025.
• Meet with the FDA in an end of Phase 2 meeting in the third quarter of 2025.

Key Dates

Keywords

CNM-Au8, ALS, Multiple Sclerosis, MS, Clinical Trials, NDA, Research and Development, Financial Results, Going Concern, Warrants, Financing, Clene Inc.